Markers of inflammation and cognitive decline in an African-Caribbean population

International Journal of Geriatric Psychiatry

Volumn 22, Issue 10, 2007, Pages 966-973

  Jordanova, Vesna ^a   Stewart, Robert ^a   Davies, Emma ^b   Sherwood, Roy ^c   Prince, Martin ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

African Caribbean; C reactive protein; Cognitive decline; Interleukin 6; Non steroidal anti inflammatory agents; Serum amyloid A

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; INTERLEUKIN 6; NONSTEROID ANTIINFLAMMATORY AGENT; SERUM AMYLOID A;

ADULT; AFRICAN CARIBBEAN; AGED; ARTICLE; COGNITIVE DEFECT; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; IMMUNOASSAY; INFLAMMATION; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; ORIENTATION; PATHOGENESIS; PREDICTION; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PSYCHOMETRY; PSYCHOMOTOR DISORDER; RISK FACTOR; SHORT TERM MEMORY; UNITED KINGDOM; VERBAL MEMORY;

EID: 35448936474     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.1772     Document Type: Article

References (36)

1. Barrett-Connor E, Edelstein SL, Corey-Bloom J, Wiederholt WC. 1996. Weight loss precedes dementia in community-dwelling older adults. J Am Geriatr Soc 44: 1147-1152.
2. Cesari M, Penninx BW, Newman AB, et al. 2003. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 108: 2317-2322.
3. Cox BD, Huppert FA, Wichelow MJ. 1993. The Health and Lifestyle Survey: Seven Years On. Dartmouth Publishing Co. Ltd.: Aldershot.
4. Dik MG, Jonker C, Hack CE, et al. 2005. Serum inflammatory proteins and cognitive decline in older persons. Neurology 64: 1371-1377.
5. Elwan O, Madkour O, Elwan F, et al. 2003. Brain aging in normal Egyptians: cognition, education, personality, genetic and immunological study. J Neurol Sci 211: 15-22.
6. Engelhart M J, Geerlings MI, Meijer J, et al. 2004. Inflammatory proteins in plasma and the risk of dementia. Arch Neurol 61: 668-672.
7. Ershler WB, Keller ET. 2000. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med 51: 245-270.
8. Folstein M, Folstein S, McHugh P. 1975. 'Mini-Mental State', a practical method for grading the cognitive state of patients for the clinician. J Psychiat Res 12: 189-198.
9. Ford ES, Giles WH. 2000. Serum C-reactive protein and self-reported stroke. Findings from the Third National Health and Nutrition Examination Survey. Arterioscler Thromb Vasc Biol 20: 1047-1051.
10. Guruje O, Unverzagt FW, Osuntokun BO, et al. 1995. The CERAD neuropsychological test battery: norms from a Yoruba-speaking Nigerian sample. W Afr J Med 14: 29-33.
11. Hoffmeister A, Rothenbacher D, Bazner U, et al. 2001. Role of novel markers of inflammation in patients with stable coronary heart disease. Am J Cardiol 87: 262-266.
12. Holmes C, El-Okl M, Williams AL, et al. 2003. Systemic infection, interleukin 1β, and cognitive decline in Alzheimer's disease. J Neurol Neurosurg Psychiatry 74: 788-789.
13. Iwamoto N, Nishiyama E, Ohwada J, Arui H. 1994. Demonstration of CRP immunoreactivity in brains of Alzheimer's disease: immunohistochemical study using formic acid pretreatment of tissue sections. Neurosci Lett 177: 23-26.
14. Koenig W, Sund M, Frohlich M, et al. 1999. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99: 237-242.
15. Licastro F, Pedrini S, Caputo L, et al. 2000. Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? J Neuroimmunol 103: 97-102.
16. Maes M, De Vos N, Wanters A, et al. 1999. Inflammatory markers in younger vs elderly normal volunteers and in patients with Alzheimer's disease. J Psychiat Res 33: 397-405.
17. Morris JC, Heyman A, Mohs RC, et al. 1989. The consortium to establish a registry for Alzheimer's disease (CERAD). Part 1. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 39: 1159-1165.
18. Morrow DA, Rifai N, Antman EM, et al. 2000. Serum amyloid A predicts early mortality in acute coronary syndromes: a TIMI 11A substudy. J Am Coll Cardiol 35: 358-362.
19. Prince MJ, Harwood RH, Blizard RA, et al. 1997. Impairment, disability and handicap as risk factors for depression in old age. The Gospel Oak Project V. Psychol Med 27: 311-321.
20. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. 2000. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101: 1767-1772.
21. Rosler N, Wichart I, Jellinger KA. 2001. Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer's disease patients. J Neural Transmission 108: 231-246.
22. Schmidt R, Schmidt H, Curb JD, et al. 2002. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol 52: 168-174.
23. Singh VK, Guthikonda P. 1997. Circulating cytokines in Alzheimer's disease. J Psychiat Res 31: 657-660.
24. Stewart JA, Dundas R, Howard RS, et al. 1999. Ethnic differences in incidence of stroke: prospective study with stroke register. BMJ 318: 967-971.
25. Stewart R, Johnson J, Richards M, et al. Medical Research Council Cognitive Function and Ageing Study. 2002. The distribution of Mini-Mental State Examination scores in an older UK African-Caribbean population compared with MRC CFA Study norms, Int J Geriatr Psychiatry 17: 745-751.
26. Stewart R, Masaki K, Xue Q-L, et al. 2005. A 32-year prospective study of change in body weight and incident dementia: the Honolulu-Asia Aging Study. Arch Neural 62: 55-60.
27. Stewart R, Powell J, Prince M, Mann A. 2004. ACE genotype and cognitive decline in an African-Caribbean population. Neurobiol Aging 25: 1369-1375.
28. Stewart R, Prince M, Mann A. 2003. Age, vascular risk, and cognitive decline in an older, British African-Caribbean population. J Am Geriatr Soc 51: 1547-1553.
29. Stewart R, Richards M, Brayne C, Mann A. 2001a. Cognitive function in UK community-dwelling African Caribbean elders: normative data for a test battery, Int J Geriatr Psychiatry 16: 518-527.
30. Stewart R, Richards M, Brayne C, Mann A. 2001b. Vascular risk and cognitive impairment in an older, British, African-Caribbean population. J Am Geriatr Soc 49: 263-269.
31. Teunissen CE, Van Boxtel MP, Bosma H, et al. 2003. Inflammation markers in relation to cognition in a healthy aging population. J Neuroimmunol 134: 142-150.
32. Weaver JD, Huang MH, Albert M, et al. 2002. Interleukin-6 and risk of cognitive decline: MacArthur studies of successful aging. Neurology 59: 371-378.
33. Welsh KA, Fillenbaum G, Wilkinson W, et al. 1995. Neuropsychological test performance in African-American and white patients with Alzheimer's disease. Neurology 45: 2207-2211.
34. Whitty CJ, Brenner EJ, Shipley MJ, et al. 1999. Differences in biological risk factors for cardiovascular disease between three ethnic groups in the Whitehall II study. Atherosclerosis 142: 279-286.
35. World Health Organisation. 1993. Report of a Consultation on Development of a WHO/MNH Battery of Cognitive Assessment Instruments. WHO: Geneva.
36. Yaffe K, Lindquist MS, Penninx BW, et al. 2003. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology 61: 76-80.